PL2263751T3 - Isoxazole compound for the treatment of gastrointestinal cancers - Google Patents
Isoxazole compound for the treatment of gastrointestinal cancersInfo
- Publication number
- PL2263751T3 PL2263751T3 PL10174276T PL10174276T PL2263751T3 PL 2263751 T3 PL2263751 T3 PL 2263751T3 PL 10174276 T PL10174276 T PL 10174276T PL 10174276 T PL10174276 T PL 10174276T PL 2263751 T3 PL2263751 T3 PL 2263751T3
- Authority
- PL
- Poland
- Prior art keywords
- treatment
- gastrointestinal cancers
- isoxazole compound
- isoxazole
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07118421 | 2007-10-12 | ||
| EP10174276.5A EP2263751B1 (en) | 2007-10-12 | 2008-10-10 | Isoxazole compound for the treatment of gastrointestinal cancers |
| EP08836801.4A EP2209529B1 (en) | 2007-10-12 | 2008-10-10 | Isoxazole compound for the treatment of breast cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2263751T3 true PL2263751T3 (en) | 2014-12-31 |
Family
ID=38952098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10174276T PL2263751T3 (en) | 2007-10-12 | 2008-10-10 | Isoxazole compound for the treatment of gastrointestinal cancers |
Country Status (19)
| Country | Link |
|---|---|
| US (6) | US20100210650A1 (en) |
| EP (3) | EP2209529B1 (en) |
| JP (2) | JP5800504B2 (en) |
| KR (4) | KR20100075902A (en) |
| CN (2) | CN104306377A (en) |
| AU (1) | AU2008309562B2 (en) |
| BR (1) | BRPI0818559A2 (en) |
| CA (1) | CA2700795C (en) |
| CL (1) | CL2008003005A1 (en) |
| ES (1) | ES2500920T3 (en) |
| MA (1) | MA31765B1 (en) |
| MX (1) | MX2010003988A (en) |
| PL (1) | PL2263751T3 (en) |
| PT (1) | PT2263751E (en) |
| RU (1) | RU2491938C2 (en) |
| TN (1) | TN2010000139A1 (en) |
| TW (1) | TW200922595A (en) |
| WO (1) | WO2009047323A2 (en) |
| ZA (1) | ZA201001546B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2624493C2 (en) * | 2011-10-14 | 2017-07-04 | Новартис Аг | 2-carboxamide cycloamino urea derivatives in combination with hsp90 inhibitors for treating proliferative diseases |
| US20160031836A1 (en) * | 2013-03-15 | 2016-02-04 | Novartis Ag | Biomarker |
| JP6533866B2 (en) * | 2015-08-24 | 2019-06-19 | 山西亜宝保健品有限公司Ｓｈａｎｘｉ Ｙａｂａｏ Ｈｅａｌｔｈ Ｐｒｏｄｕｃｔｓ Ｃｏ．，Ｌｔｄ． | Use of dihydroxyacetone for producing antineoplastic agents |
| KR102653960B1 (en) * | 2020-07-23 | 2024-04-03 | 의료법인 성광의료재단 | Immune checkpoint inhibitor combination therapy for treating cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003282512A1 (en) * | 2002-10-22 | 2004-05-13 | The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services | Methods of reducing the activity of and reducing the concentration of a mutant kit protein |
| EP1611112B1 (en) * | 2003-02-11 | 2012-08-22 | Vernalis (Cambridge) Limited | Isoxazole compounds as inhibitors of heat shock proteins |
| US20050054625A1 (en) * | 2003-05-30 | 2005-03-10 | Kosan Biosciences, Inc. | Method for treating diseases using HSP90-inhibiting agents in combination with nuclear export inhibitors |
| CN101198596A (en) * | 2005-04-14 | 2008-06-11 | 诺华疫苗和诊断公司 | 2-amino-quinaz0lin-5-ones as HSP90 inhibitors useful in treating proliferation diseases |
| US20070105862A1 (en) * | 2005-11-10 | 2007-05-10 | Milan Bruncko | Heat-shock protein binders |
| ATE552836T1 (en) * | 2007-03-01 | 2012-04-15 | Novartis Ag | 5-(2,4-DIHYDROXY-5-ISOPROPYL-PHENYL)-4-(4-MORPHOLINE-4-YLMETHYL-PHENYL)-ISOXAZOLE-3-CARBOXYLIC ACID-ETHYLAMIDE MESYLATE, ITS HYDRATES AND POLYMORPHES, AND FORMULATIONS CONTAINING THESE FORMS |
-
2008
- 2008-10-09 TW TW097139091A patent/TW200922595A/en unknown
- 2008-10-10 KR KR1020107007726A patent/KR20100075902A/en not_active Application Discontinuation
- 2008-10-10 WO PCT/EP2008/063605 patent/WO2009047323A2/en active Application Filing
- 2008-10-10 KR KR1020177031591A patent/KR20170124642A/en not_active Application Discontinuation
- 2008-10-10 KR KR1020167033776A patent/KR101841872B1/en active IP Right Grant
- 2008-10-10 MX MX2010003988A patent/MX2010003988A/en active IP Right Grant
- 2008-10-10 KR KR1020167008429A patent/KR20160040738A/en not_active Application Discontinuation
- 2008-10-10 PL PL10174276T patent/PL2263751T3/en unknown
- 2008-10-10 CN CN201410455814.4A patent/CN104306377A/en active Pending
- 2008-10-10 EP EP08836801.4A patent/EP2209529B1/en not_active Not-in-force
- 2008-10-10 CL CL2008003005A patent/CL2008003005A1/en unknown
- 2008-10-10 PT PT101742765T patent/PT2263751E/en unknown
- 2008-10-10 JP JP2010528411A patent/JP5800504B2/en not_active Expired - Fee Related
- 2008-10-10 AU AU2008309562A patent/AU2008309562B2/en not_active Ceased
- 2008-10-10 US US12/680,657 patent/US20100210650A1/en not_active Abandoned
- 2008-10-10 CA CA2700795A patent/CA2700795C/en not_active Expired - Fee Related
- 2008-10-10 EP EP18187344.9A patent/EP3427797A1/en not_active Withdrawn
- 2008-10-10 ES ES10174276.5T patent/ES2500920T3/en active Active
- 2008-10-10 EP EP10174276.5A patent/EP2263751B1/en not_active Not-in-force
- 2008-10-10 BR BRPI0818559 patent/BRPI0818559A2/en not_active Application Discontinuation
- 2008-10-10 CN CN200880105578A patent/CN101795728A/en active Pending
- 2008-10-10 RU RU2010118458/15A patent/RU2491938C2/en not_active IP Right Cessation
-
2010
- 2010-03-03 ZA ZA201001546A patent/ZA201001546B/en unknown
- 2010-03-26 TN TNP2010000139A patent/TN2010000139A1/en unknown
- 2010-04-08 MA MA32755A patent/MA31765B1/en unknown
-
2011
- 2011-12-08 US US13/314,584 patent/US20120083496A1/en not_active Abandoned
-
2012
- 2012-05-02 US US13/461,855 patent/US20120214813A1/en not_active Abandoned
-
2014
- 2014-05-02 US US14/267,946 patent/US20140288075A1/en not_active Abandoned
- 2014-05-02 JP JP2014095330A patent/JP2014156475A/en not_active Withdrawn
-
2015
- 2015-10-28 US US14/925,263 patent/US20160045513A1/en not_active Abandoned
-
2016
- 2016-04-12 US US15/096,397 patent/US20160220576A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1256861A1 (en) | Compositions for the treatment of gastrointestinal inflammation | |
| HK1208237A1 (en) | Methods for the treatment of gout | |
| HUE043569T2 (en) | Compounds for the treatment of cancer | |
| IL200090A0 (en) | Composition for treatment of undifferentiated-type of gastric cancer | |
| IL232406A (en) | Therapeutic isoxazole compounds | |
| EP2049139A4 (en) | Treatment of ras-expressing tumors | |
| PL3199180T3 (en) | Epha3 antibodies for the treatment of solid tumors | |
| ZA201003425B (en) | 5-cyano-thienopyridines for the treatment of tumors | |
| EP2212305A4 (en) | Beta-lactone compounds | |
| IL210066A0 (en) | Novel ortho-aminoanilides for the treatment of cancer | |
| HK1254607A1 (en) | Organoarsenic compound for the treatment of cancer | |
| PT2263751E (en) | Isoxazole compound for the treatment of gastrointestinal cancers | |
| EP2352501A4 (en) | Compounds for the treatment of osteoporosis and cancers | |
| IL201318A0 (en) | Use of hdac inhibitors for the treatment of gastrointestinal cancers | |
| GB0719613D0 (en) | The treatment of pruritis | |
| GB0817857D0 (en) | Compounds for the treatment of neoplasia | |
| GB0819536D0 (en) | Compounds for the treatment of neoplasia | |
| GB0604114D0 (en) | Combinations for the treatment of cancer | |
| PL2214677T3 (en) | Compositions for the treatment of inflammation of the gastrointestinal tract | |
| ZA201001594B (en) | Vaccine for the treatment of osteoarthritis | |
| GB0712513D0 (en) | Treatment of cancer |